D
The Oncology Institute, Inc.
TOI
$0.716
$0.09114.56%
D
Sell
3/4/2025Upgraded
The Oncology Institute, Inc. (TOI) was upgraded to D- from E+ on 3/4/2025 due to an increase in the total return index and valuation index.
The Oncology Institute, Inc. (TOI) was upgraded to D- from E+ on 3/4/2025 due to an increase in the total return index and valuation index.
E
Sell
2/7/2025Downgrade
The Oncology Institute, Inc. (TOI) was downgraded to E+ from D- on 2/7/2025 due to a decline in the valuation index and growth index.
The Oncology Institute, Inc. (TOI) was downgraded to E+ from D- on 2/7/2025 due to a decline in the valuation index and growth index.
D
Sell
1/21/2025Upgraded
The Oncology Institute, Inc. (TOI) was upgraded to D- from E+ on 1/21/2025 due to an increase in the volatility index and total return index.
The Oncology Institute, Inc. (TOI) was upgraded to D- from E+ on 1/21/2025 due to an increase in the volatility index and total return index.
E
Sell
11/19/2024Downgrade
The Oncology Institute, Inc. (TOI) was downgraded to E+ from D- on 11/19/2024 due to a decline in the volatility index, growth index and solvency index. Debt to equity increased from 3.3 to 6.35, the quick ratio declined from 2.87 to 2.19, and earnings per share declined from -$0.17 to -$0.18.
The Oncology Institute, Inc. (TOI) was downgraded to E+ from D- on 11/19/2024 due to a decline in the volatility index, growth index and solvency index. Debt to equity increased from 3.3 to 6.35, the quick ratio declined from 2.87 to 2.19, and earnings per share declined from -$0.17 to -$0.18.
D
Sell
11/12/2024Upgraded
The Oncology Institute, Inc. (TOI) was upgraded to D- from E+ on 11/12/2024 due to a large increase in the growth index, volatility index and valuation index. Earnings per share increased from -$0.22 to -$0.17, EBIT increased 8.95% from -$17.97M to -$16.36M, and total revenue increased 4.13% from $94.67M to $98.58M.
The Oncology Institute, Inc. (TOI) was upgraded to D- from E+ on 11/12/2024 due to a large increase in the growth index, volatility index and valuation index. Earnings per share increased from -$0.22 to -$0.17, EBIT increased 8.95% from -$17.97M to -$16.36M, and total revenue increased 4.13% from $94.67M to $98.58M.
E
Sell
5/23/2024Downgrade
The Oncology Institute, Inc. (TOI) was downgraded to E+ from D on 5/23/2024 due to a large decline in the efficiency index, solvency index and volatility index. Debt to equity increased from 1.63 to 2.3, the quick ratio declined from 3.62 to 2.73, and total capital declined 8.81% from $176.7M to $161.13M.
The Oncology Institute, Inc. (TOI) was downgraded to E+ from D on 5/23/2024 due to a large decline in the efficiency index, solvency index and volatility index. Debt to equity increased from 1.63 to 2.3, the quick ratio declined from 3.62 to 2.73, and total capital declined 8.81% from $176.7M to $161.13M.
D
Sell
8/15/2023Upgraded
The Oncology Institute, Inc. (TOI) was upgraded to D from D- on 8/15/2023 due to an increase in the volatility index and total return index.
The Oncology Institute, Inc. (TOI) was upgraded to D from D- on 8/15/2023 due to an increase in the volatility index and total return index.
D
Sell
7/28/2023Downgrade
The Oncology Institute, Inc. (TOI) was downgraded to D- from D on 7/28/2023 due to a decline in the volatility index.
The Oncology Institute, Inc. (TOI) was downgraded to D- from D on 7/28/2023 due to a decline in the volatility index.
D
Sell
7/11/2023Upgraded
The Oncology Institute, Inc. (TOI) was upgraded to D from D- on 7/11/2023 due to an increase in the volatility index and total return index.
The Oncology Institute, Inc. (TOI) was upgraded to D from D- on 7/11/2023 due to an increase in the volatility index and total return index.
D
Sell
6/22/2023Downgrade
The Oncology Institute, Inc. (TOI) was downgraded to D- from D on 6/22/2023 due to a decline in the volatility index and total return index.
The Oncology Institute, Inc. (TOI) was downgraded to D- from D on 6/22/2023 due to a decline in the volatility index and total return index.
D
Sell
6/2/2023Upgraded
The Oncology Institute, Inc. (TOI) was upgraded to D from D- on 6/2/2023 due to an increase in the volatility index.
The Oncology Institute, Inc. (TOI) was upgraded to D from D- on 6/2/2023 due to an increase in the volatility index.
D
Sell
5/17/2023Downgrade
The Oncology Institute, Inc. (TOI) was downgraded to D- from D on 5/17/2023 due to a decline in the solvency index, volatility index and efficiency index. Net income declined 172.54% from -$11.01M to -$30M, debt to equity increased from 0.7 to 0.89, and the quick ratio declined from 3.84 to 3.38.
The Oncology Institute, Inc. (TOI) was downgraded to D- from D on 5/17/2023 due to a decline in the solvency index, volatility index and efficiency index. Net income declined 172.54% from -$11.01M to -$30M, debt to equity increased from 0.7 to 0.89, and the quick ratio declined from 3.84 to 3.38.
D
Sell
5/11/2023Upgraded
The Oncology Institute, Inc. (TOI) was upgraded to D from D- on 5/11/2023 due to an increase in the volatility index.
The Oncology Institute, Inc. (TOI) was upgraded to D from D- on 5/11/2023 due to an increase in the volatility index.
D
Sell
4/25/2023Downgrade
The Oncology Institute, Inc. (TOI) was downgraded to D- from D on 4/25/2023 due to a decline in the volatility index and total return index.
The Oncology Institute, Inc. (TOI) was downgraded to D- from D on 4/25/2023 due to a decline in the volatility index and total return index.
D
Sell
4/5/2023Upgraded
The Oncology Institute, Inc. (TOI) was upgraded to D from D- on 4/5/2023 due to an increase in the volatility index and valuation index.
The Oncology Institute, Inc. (TOI) was upgraded to D from D- on 4/5/2023 due to an increase in the volatility index and valuation index.
D
Sell
3/20/2023Downgrade
The Oncology Institute, Inc. (TOI) was downgraded to D- from D on 3/20/2023 due to a major decline in the solvency index, efficiency index and growth index. Net income declined 311.63% from -$2.67M to -$11.01M, earnings per share declined from -$0.1731 to -$0.201, and debt to equity increased from 0.66 to 0.7.
The Oncology Institute, Inc. (TOI) was downgraded to D- from D on 3/20/2023 due to a major decline in the solvency index, efficiency index and growth index. Net income declined 311.63% from -$2.67M to -$11.01M, earnings per share declined from -$0.1731 to -$0.201, and debt to equity increased from 0.66 to 0.7.
D
Sell
5/12/2022Upgraded
The Oncology Institute, Inc. (TOI) was upgraded to D from D- on 5/12/2022 due to a significant increase in the efficiency index, growth index and solvency index. Net income increased 289.89% from -$10.16M to $19.29M, earnings per share increased from -$0.1452 to $0.2083, and EBIT increased 55.27% from -$40.36M to -$18.05M.
The Oncology Institute, Inc. (TOI) was upgraded to D from D- on 5/12/2022 due to a significant increase in the efficiency index, growth index and solvency index. Net income increased 289.89% from -$10.16M to $19.29M, earnings per share increased from -$0.1452 to $0.2083, and EBIT increased 55.27% from -$40.36M to -$18.05M.
D
Sell
5/5/2022Upgraded
The Oncology Institute, Inc. (TOI) was upgraded to D- from E+ on 5/5/2022 due to an increase in the total return index and volatility index.
The Oncology Institute, Inc. (TOI) was upgraded to D- from E+ on 5/5/2022 due to an increase in the total return index and volatility index.
E
Sell
4/20/2022Downgrade
The Oncology Institute, Inc. (TOI) was downgraded to E+ from D- on 4/20/2022 due to a decline in the valuation index, total return index and volatility index.
The Oncology Institute, Inc. (TOI) was downgraded to E+ from D- on 4/20/2022 due to a decline in the valuation index, total return index and volatility index.
D
Sell
3/15/2022Downgrade
The Oncology Institute, Inc. (TOI) was downgraded to D- from D on 3/15/2022 due to a significant decline in the valuation index, efficiency index and total return index. Net income declined 240.8% from -$2.98M to -$10.16M.
The Oncology Institute, Inc. (TOI) was downgraded to D- from D on 3/15/2022 due to a significant decline in the valuation index, efficiency index and total return index. Net income declined 240.8% from -$2.98M to -$10.16M.
D
Sell
12/21/2021None
The Oncology Institute, Inc. (TOI) was downgraded to D from U on 12/21/2021.
The Oncology Institute, Inc. (TOI) was downgraded to D from U on 12/21/2021.
NASDAQ
03/07/2025 4:00PM Eastern
Quotes delayed
